

Delivering Innovation to the Eye

HC Wainwright Conference

March 9, 2021



EYEPOINT[®]
PHARMACEUTICALS

Forward Looking Statements

Various statements made in this presentation are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expectations regarding the potential benefits of our partnerships and strategic alliances with other companies, as well as the timing and clinical development of our product candidates, including EYP-1901; the potential for EYP-1901 as a vital, novel twice-yearly treatment for wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion; preliminary financial information as of December 31, 2020; and our longer term financial and business goals, are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the extent to which COVID-19 impacts our business; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ® and DEXYCU® and to successfully commercialize YUTIQ and DEXYCU in the U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the development of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; the success of current and future license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; termination or breach of current license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of our stock price; possible dilution; absence of dividends; the potential for our preliminary financial information to change in connection with the finalization of our financial results for the fourth quarter and full year 2020; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

COMPANY OVERVIEW

Proven technology driving pipeline growth

Compelling pipeline focused on retinal disease

- EYP-1901 - potential twice yearly treatment for wet AMD, diabetic retinopathy and retinal vein occlusion
- YUTIQ50 – potential twice yearly treatment for posterior uveitis
- R&D collaborations leveraging Durasert®

Durasert® - FDA validated drug delivery platform

- Sustained (zero-order kinetics) local delivery of drug product
- Provides constant and stable release of therapeutics in the eye over weeks, months or years
- Administered safely to thousands of patients' eyes across four FDA approved products including YUTIQ®


Commercializing two FDA-approved products - YUTIQ® and DEXYCU®

- Positioned for 2021 growth as physicians adjust to COVID-19 environment

TECHNOLOGY

DURASERT® Platform


Proven sustained release
intraocular drug delivery



TECHNOLOGY

DURASERT®

**Proven sustained
release delivery**



Four FDA-approved products with multiple programs in development

- Single intravitreal injection
- Continuous, stable release to the back of the eye provides consistent and reliable drug delivery over weeks, months or years
- Simple administration in physician's office

Approved products/Indications

- YUTIQ® (2018, EyePoint) - Posterior Segment Uveitis
- ILUVIEN® (2014, Alimera) - DME
- RETISERT® (2005, B&L) - Uveitis
- VITRASERT® (1996, B&L) - CMV retinitis

Development Candidates

- EYP-1901 for Wet AMD
- YUTIQ® 50 for Posterior Segment Uveitis
- Partner programs




PIPELINE

Building on a Proven Platform

Retinal disease focused pipeline

PIPELINE PROGRAMS	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
EYP-1901- anti-VEGF bioerodible Durasert • Wet AMD • Diabetic retinopathy • Retinal vein occlusion				
YUTIQ® 50 - chronic non-infectious uveitis				
Durasert Partners	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
Ophthalmology R&D collaboration				
Non-ophthalmology R&D collaboration				




PIPELINE


EYP-1901 - Potential Twice a Year Anti-VEGF Treatment

Our goal is nothing short of transforming the treatment of wet AMD, diabetic retinopathy, and retinal vein occlusion

PIPELINE

EYP-1901

Opportunity to transform the treatment of wet AMD



The need...

Currently, wet AMD patients often lose vision despite anti-VEGF therapy due to undertreatment


The EYP-1901 solution...

Potential twice yearly in-office injection of anti-VEGF therapy

- Anti-VEGF therapy (vorolanib) delivered via intravitreal injection using bioerodible Durasert
- Sustained, stable release may lead to better visual outcomes through steady receptor blocking


PIPELINE

EYP-1901



Real world need... today's wet AMD treatments still result in vision loss over time

RETROSPECTIVE, OBSERVATIONAL STUDY IN 2,227 PATIENTS WITH WET AMD




Holz FG, et al. Br J Ophthalmol 2015;99:220–226. doi:10.1136/bjophthalmol-2014-305327


...including real world data from the U.S.

PIPELINE

EYP-1901




RETROSPECTIVE STUDY OF 3350 RANIBIZUMAB AND 4300 AFLIBERCEPT TREATMENT-NAIVE EYES WITH WET AMD



Lotery et al., Eye (2017) 31, 1697–1706

PIPELINE

EYP-1901



The EYP-1901 solution

EYP-1901

- Intravitreal delivery of vorolanib using a bioerodible formulation of Durasert®


Vorolanib

- Tyrosine kinase inhibitor (TKI) studied as an oral therapy for wet AMD through Phase 2 with strong clinical signal and no significant ocular adverse events
- Blocks all 3 isoforms of VEGFR, the main driver of the proliferation of blood vessels that are the hallmark of wet AMD


Effective blocking of VEGFR prevents neovascularization and loss of vision

PIPELINE

EYP-1901




VEGF SIGNALING PATHWAYS



PIPELINE

EYP-1901



A potent inhibitor of VEGFR

Vorolanib blocks VEGF receptors at the same level as sunitinib, a proven anti-VEGF therapy

BIOCHEMICAL SELECTIVITY (IC50, ng/mL)	
SUNITINIB	22.9
VOROLANIB	22.9


The inhibitor constant (Ki) of sunitinib for VEGFR is reported to be low (5 ng/g), an indication on strong inhibition. Since Ki is related to IC50, similar inhibition Ki is expected for vorolanib.

Oral vorolanib clinical results – Phase 1

Demonstrated clinical activity in wet AMD

PIPELINE

EYP-1901



Phase 1 trial design


- Open label, 24 weeks, dose escalation, no control, oral delivery; 80% of eyes enrolled previously treated; 4 eyes treatment naïve
- N=25

Phase 1 results

- BCVA was maintained to within 4 letters of baseline at the 24-week endpoint, or improved in all but 1 participant
- 60% (15/25) of patients required no rescue injection while on oral vorolanib therapy
- Mean OCT thickness in completers was reduced by $-50 \pm 97 \mu\text{m}$; Mean OCT thickness in treatment-naïve patients was reduced by $\sim 80 \mu\text{m}$

PIPELINE

EYP-1901



Oral vorolanib clinical activity in wet AMD

Phase 2 trial

Less rescue vs placebo for all doses
with no ocular toxicity

For subjects followed $\geq$ 6 months	Placebo n=33	50 mg n=34	100 mg n=30	200 mg n=26
Median number of anti-VEGF injections*	9.0	6.1	5.8	4.6
Percent of Patients w/ no rescue	2.6	7.5	10.3	20.5

Strict pre-defined rescue criteria with anti-VEGF therapy

- Any increase in fluid on OCT compared to screening visit 2 (~14 days after an IVT injection)
- New or increased macular hemorrhage by fundus photography

* Normalized for number of months on study
Study performed by Tyrogeix





EYP-1901 Phase 1 Trial

Phase 1 DAVIO wet AMD clinical trial


PIPELINE

EYP-1901




PIPELINE

EYP-1901



Phase 1 DAVIO wet AMD clinical trial underway



A young girl with long brown hair and blue eyes, wearing a blue knit sweater, is looking up and to the right. An older woman with short grey hair, wearing a red top, is behind her, also looking up and pointing her right index finger towards the upper right. The background is a warm, out-of-focus orange and yellow light.

PRODUCTS


FDA Approved Commercial Products

PRODUCTS



**CONTINUOUS CALM
IN UVEITIS**

Approved for the treatment of chronic non-infectious uveitis affecting the back of the eye



- Commercially launched in U.S. in 2019
- Patent protection to August 2027
- Constant and stable release of fluocinolone with Durasert helps prevent uveitis flares for up to 3 years

LICENSE AGREEMENTS

Alimera Sciences, Inc. has rights for non-infectious posterior uveitis in the EMEA

Rights for China, Hong Kong, Taiwan, Macau, Korea and certain SE Asia countries licensed to Ocumension with a royalty on sales payable to EyePoint

PRODUCTS



Chronic non-infectious uveitis causes blindness with every flare

60K–100K patients are suffering from uveitis in the U.S.

The need

- Flares can cause blindness
- 30,000 Americans become blind each year because of uveitis
- Uveitis lasts a lifetime and often affects people in middle age

The YUTIQ answer

- 3-year continuous treatment in a single injection that controls flares and preserves eyesight
- Simple administration in the physician's office
- Gives patients and physicians the confidence that comes with three years of assured compliance

PRODUCTS

0.18 mg


YUTIQ™

(fluocinolone acetonide
intravitreal implant) 0.18 mg

CONTINUOUS CALM
IN UVEITIS

Continuous 3-year delivery limits blindness-causing uveitis flares


Time to recurrence of uveitis within 36 months



US Phase 3 Trial

Customer demand returning from COVID shutdowns

PRODUCTS



PRODUCTS



DEXYCU[®]

(dexamethasone intraocular
suspension) 9%

TARGET THE SITE

Treatment of inflammation following ocular surgery

- Single long-lasting injectable treatment compared to low compliance eyedrop regimen
- Effective in preventing inflammation after cataract surgery with proven safety record
- Co-promoted with ImprimisRX, an established commercial organization in the cataract space



LICENSE AGREEMENT

Rights for China, Hong Kong, Taiwan, Macau , Korea and certain SE Asia countries licensed to Ocumension with a royalty on sales payable to EyePoint

PRODUCTS



DEXYCU[®]
(dexamethasone intraocular
suspension) 9%

TARGET THE SITE

The U.S. cataract surgery market is large and growing

3.8 million cataract surgeries in 2018

The need

- As the baby boom generation ages, cataract surgery will become even more common

The DEXYCU answer

- Today, eyedrops are the most common treatment after cataract surgery
- Patients forget to take their eye drops, leading to unnecessary complications
- Dexycu is injected into the eye at the time of surgery so compliance is not an issue


Customer demand returning from COVID shutdowns

PRODUCTS



DEXYCU[®]
(dexamethasone intraocular
suspension) 9%

TARGET THE SITE



DELIVERING INNOVATION
TO THE EYE

Financial Summary

Solid cash position and growing revenues

- **\$44.9 million of Cash on December 31, 2020**
- **\$115 million follow-on offering completed in February 2021**
- **2020 total revenues of \$34.4 million, including \$20.8 million of net product revenue**
 - **2019 Total revenues of \$20.3 million including \$16.8 million on net product revenues**

Delivering Innovation to the Eye

